InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,440.52
(
0.16%
)
US TECH 100
19,180.00
(
0.06%
)
Dow Jones
38,593.85
(
0.01%
)
Brent Oil
83.04
(
1.11%
)
Bitcoin
65,592.58
(
-1.57%
)
Post# of 438
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DanWebzster

Send PM Follow Ignore
Followers 10
Posts 1060
Boards Moderated 2
Alias Born 09/04/2000

DanWebzster

Member Level

Re: DanWebzster post# 130

Monday, 04/30/2018 1:14:27 PM

Monday, April 30, 2018 1:14:27 PM

Post# of 438
HRTX may have the best CEO in small-cap biotech.

Recent Ph3 results fro post-operative pain set it up for FDA approval and opioid-sparing status

PDUFA for post operative pain should be set for mid-2019.

CINV franchise is still growing. TSRO will stop promoting competing treatment, due to safety issues.

EOY/17 Cash = $172.4mn with AR = $41.8mn The high AR was due to a lack of J-code for CINV franchise.

Since EOY/17, HRTX acquired the J-code and raised $169mn in an offering.

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up